These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 15569312

  • 1. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
    Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moysés RM, Jorgetti V.
    Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
    [Abstract] [Full Text] [Related]

  • 2. Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure.
    Martínez-Arias L, Panizo-García S, Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, Avello-Llano N, Miguel-Fernández D, Ruíz Torres MP, Cannata-Andía JB, Carrillo-López N, Naves-Díaz M.
    Nefrologia (Engl Ed); 2021 Dec; 41(6):640-651. PubMed ID: 36165154
    [Abstract] [Full Text] [Related]

  • 3. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
    Geng Z, Monier-Faugere MC, Bauss F, Malluche HH.
    Clin Nephrol; 2000 Jul; 54(1):45-53. PubMed ID: 10939756
    [Abstract] [Full Text] [Related]

  • 4. Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats.
    Oste L, Behets GJ, Dams G, Bervoets AR, Marynissen RL, Geryl H, Van Hoof VO, De Broe ME, D'Haese PC.
    Ren Fail; 2007 Jul; 29(1):1-12. PubMed ID: 17365904
    [Abstract] [Full Text] [Related]

  • 5. Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure.
    Martínez-Arias L, Panizo-García S, Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, Avello-Llano N, Miguel-Fernández D, Ruiz Torres MP, Cannata-Andía JB, Carrillo-López N, Naves-Díaz M.
    Nefrologia (Engl Ed); 2021 Mar 11. PubMed ID: 33715866
    [Abstract] [Full Text] [Related]

  • 6. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E.
    Kidney Int; 2003 Nov 11; 64(5):1653-61. PubMed ID: 14531797
    [Abstract] [Full Text] [Related]

  • 7. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH.
    Kidney Int; 1999 Mar 11; 55(3):821-32. PubMed ID: 10027919
    [Abstract] [Full Text] [Related]

  • 8. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?
    Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, Dos Reis LM, Graciolli FG, Oliveira EC, Liu S, Sabbagh Y, Jorgetti V, Schiavi S, Moysés RM.
    PLoS One; 2013 Mar 11; 8(11):e79721. PubMed ID: 24236156
    [Abstract] [Full Text] [Related]

  • 9. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system.
    Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V.
    Nephrol Dial Transplant; 2012 Apr 11; 27(4):1437-45. PubMed ID: 21825304
    [Abstract] [Full Text] [Related]

  • 10. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.
    Bover J, Jara A, Trinidad P, Rodriguez M, Felsenfeld AJ.
    Bone; 1999 Sep 11; 25(3):279-85. PubMed ID: 10495131
    [Abstract] [Full Text] [Related]

  • 11. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y, Zhang H, Li Y, Li Q, Zuo L.
    Bone; 2014 Jan 11; 58():168-76. PubMed ID: 24145307
    [Abstract] [Full Text] [Related]

  • 12. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
    Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N.
    Kidney Int; 2003 Aug 11; 64(2):441-50. PubMed ID: 12846739
    [Abstract] [Full Text] [Related]

  • 13. The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia.
    Bover J, Jara A, Trinidad P, Rodriguez M, Martin-Malo A, Felsenfeld AJ.
    Kidney Int; 1994 Aug 11; 46(2):310-7. PubMed ID: 7967341
    [Abstract] [Full Text] [Related]

  • 14. Parathyroid removal prevents the progression of chronic renal failure induced by high protein diet.
    Shigematsu T, Caverzasio J, Bonjour JP.
    Kidney Int; 1993 Jul 11; 44(1):173-81. PubMed ID: 8355459
    [Abstract] [Full Text] [Related]

  • 15. Vascular calcification: contribution of parathyroid hormone in renal failure.
    Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, Custódio MR, Batista DG, Jorgetti V, Moysés RM.
    Kidney Int; 2007 Jun 11; 71(12):1262-70. PubMed ID: 17410101
    [Abstract] [Full Text] [Related]

  • 16. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E.
    J Am Soc Nephrol; 2002 Sep 11; 13(9):2299-308. PubMed ID: 12191974
    [Abstract] [Full Text] [Related]

  • 17. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
    Malluche HH, Monier-Faugere MC.
    Clin Nephrol; 1999 Nov 11; 52(5):267-77. PubMed ID: 10584989
    [Abstract] [Full Text] [Related]

  • 18. The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances.
    Batista DG, Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Dominguez WV, Neves CL, Magalhães AO, Custódio MR, Moysés RM, Jorgetti V.
    Calcif Tissue Int; 2010 Jul 11; 87(1):60-7. PubMed ID: 20428857
    [Abstract] [Full Text] [Related]

  • 19. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease.
    Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S.
    J Musculoskelet Neuronal Interact; 2005 Jun 11; 5(2):174-81. PubMed ID: 15951635
    [Abstract] [Full Text] [Related]

  • 20. Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism.
    Sanchez CP, He YZ, Leiferman E, Wilsman NJ.
    Kidney Int; 2004 May 11; 65(5):1740-8. PubMed ID: 15086913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.